DNA Biomed (Israel) Probability of Future Stock Price Finishing Under 61.96
| DNA Stock | ILS 88.60 1.60 1.84% |
DNA |
DNA Biomed Target Price Odds to finish below 61.96
The tendency of DNA Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to S 61.96 or more in 90 days |
| 88.60 | 90 days | 61.96 | about 8.87 |
Based on a normal probability distribution, the odds of DNA Biomed to drop to S 61.96 or more in 90 days from now is about 8.87 (This DNA Biomed Solns probability density function shows the probability of DNA Stock to fall within a particular range of prices over 90 days) . Probability of DNA Biomed Solns price to stay between S 61.96 and its current price of S88.6 at the end of the 90-day period is about 84.0 .
Assuming the 90 days trading horizon DNA Biomed has a beta of 0.78 suggesting as returns on the market go up, DNA Biomed average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding DNA Biomed Solns will be expected to be much smaller as well. Additionally DNA Biomed Solns has an alpha of 0.2896, implying that it can generate a 0.29 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). DNA Biomed Price Density |
| Price |
Predictive Modules for DNA Biomed
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as DNA Biomed Solns. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.DNA Biomed Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. DNA Biomed is not an exception. The market had few large corrections towards the DNA Biomed's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold DNA Biomed Solns, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of DNA Biomed within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.29 | |
β | Beta against Dow Jones | 0.78 | |
σ | Overall volatility | 9.46 | |
Ir | Information ratio | 0.06 |
DNA Biomed Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of DNA Biomed for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for DNA Biomed Solns can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| DNA Biomed Solns appears to be risky and price may revert if volatility continues | |
| The company has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist DNA Biomed until it has trouble settling it off, either with new capital or with free cash flow. So, DNA Biomed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like DNA Biomed Solns sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for DNA to invest in growth at high rates of return. When we think about DNA Biomed's use of debt, we should always consider it together with cash and equity. | |
| DNA Biomed Solns has accumulated about 492 K in cash with (2.33 M) of positive cash flow from operations. | |
| Roughly 55.0% of the company shares are held by company insiders |
DNA Biomed Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of DNA Stock often depends not only on the future outlook of the current and potential DNA Biomed's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. DNA Biomed's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 99.7 M |
DNA Biomed Technical Analysis
DNA Biomed's future price can be derived by breaking down and analyzing its technical indicators over time. DNA Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of DNA Biomed Solns. In general, you should focus on analyzing DNA Stock price patterns and their correlations with different microeconomic environments and drivers.
DNA Biomed Predictive Forecast Models
DNA Biomed's time-series forecasting models is one of many DNA Biomed's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary DNA Biomed's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about DNA Biomed Solns
Checking the ongoing alerts about DNA Biomed for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for DNA Biomed Solns help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| DNA Biomed Solns appears to be risky and price may revert if volatility continues | |
| The company has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist DNA Biomed until it has trouble settling it off, either with new capital or with free cash flow. So, DNA Biomed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like DNA Biomed Solns sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for DNA to invest in growth at high rates of return. When we think about DNA Biomed's use of debt, we should always consider it together with cash and equity. | |
| DNA Biomed Solns has accumulated about 492 K in cash with (2.33 M) of positive cash flow from operations. | |
| Roughly 55.0% of the company shares are held by company insiders |
Other Information on Investing in DNA Stock
DNA Biomed financial ratios help investors to determine whether DNA Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DNA with respect to the benefits of owning DNA Biomed security.